Early-Stop trial aims to halt blood cancer before it starts

This is a small, early-stage study to see if a drug called ropeginterferon is safe and feasible to use in people who have a specific genetic change (JAK2 mutation) that puts them at high risk for developing blood clots or a type of blood cancer. The main goal is to enroll 12 participants and closely monitor them for side effects while they receive a monthly injection for up to two years. Researchers hope this early treatment might one day prevent the progression to more serious disease.